A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

Summary

This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.

Timeline

Start

2022-07-26

Primary completion

2023-12-18

Completion

2023-12-18

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications